Real-Life Effectiveness and Tolerability of Vildagliptin and Other Oral Glucose-Lowering Therapies in Patients with Type 2 Diabetes in Germany

被引：0
|
作者：
Rüdiger Göke
Giovanni Bader
Markus Dworak
机构：
[1] Dietersdorfer Weg 2,Diabetes Center
[2] Novartis Pharma AG,undefined
[3] Novartis Pharma GmbH,undefined
来源：
Diabetes Therapy | 2014年 / 5卷
关键词：
Diabetes; Dipeptidyl peptidase 4 inhibitors; Endocrinology; Glycosylated hemoglobin; Observational study; Oral antidiabetes agents; Real life; Type 2 diabetes mellitus; Vildagliptin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：183 / 191
页数：8
相关论文
共 50 条
  • [1] Real-Life Effectiveness and Tolerability of Vildagliptin and Other Oral Glucose-Lowering Therapies in Patients with Type 2 Diabetes in Germany
    Goeke, Ruediger
    Bader, Giovanni
    Dworak, Markus
    DIABETES THERAPY, 2014, 5 (01) : 183 - 191
  • [2] Real-Life Effectiveness of Vildagliptin Compared to Sulfonylureas in Type 2 Diabetes Patients in Germany
    Dworak, Markus
    Gruenberger, Jean-Bernard
    Bader, Giovanni
    DIABETES, 2013, 62 : A285 - A285
  • [3] Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
    Prattichizzo, Francesco
    La Sala, Lucia
    Ryden, Lars
    Marx, Nikolaus
    Ferrini, Marc
    Valensi, Paul
    Ceriello, Antonio
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (2_SUPPL) : 73 - 80
  • [4] Cardiovascular Disease and Oral Agent Glucose-Lowering Therapies in the Management of Type 2 Diabetes
    Home, Philip
    DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 : S33 - S42
  • [5] Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A real-life worldwide observational study (EDGE)
    Mathieu, C.
    Barnett, A. H.
    Brath, H.
    Conget, I.
    de Castro, J. J.
    Goeke, R.
    Marquez Rodriguez, E.
    Nilsson, P. M.
    Pagkalos, E.
    Penfornis, A.
    Schaper, N. C.
    Wangnoo, S. K.
    Kothny, W.
    Bader, G.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (10) : 947 - 956
  • [6] A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes
    Wu, Tongzhi
    Little, Tanya J.
    Bound, Michelle J.
    Borg, Malcolm
    Zhang, Xiang
    Deacon, Carolyn F.
    Horowitz, Michael
    Jones, Karen L.
    Rayner, Christopher K.
    DIABETES CARE, 2016, 39 (04) : 511 - 517
  • [7] EFFECTIVENESS OF VILDAGLIPTIN COMPARED TO SULFONYLUREAS IN TYPE 2 DIABETES PATIENTS IN GERMANY: RESULTS FROM A LARGE REAL-LIFE COHORT STUDY
    Dworak, M.
    Gruenberger, J. B.
    Bader, G.
    VALUE IN HEALTH, 2012, 15 (07) : A495 - A495
  • [8] Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
    Kabadi, Udaya M.
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (01) : 140 - 140
  • [9] Glucose-lowering therapies in type 2 diabetes: Opportunities and challenges for peptides
    Bailey, Clifford J.
    PEPTIDES, 2018, 100 : 9 - 17
  • [10] Factors associated with the glucose-lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes
    Nakamura, Akinobu
    Terauchi, Yasuo
    ENDOCRINE JOURNAL, 2013, 60 (01) : 45 - 49
12345